Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Inhalation CDMO Market Evolve in Terms of Growth and Size by 2029?

The market size of the inhalation CDMO has seen significant expansion in the recent past. The market is projected to escalate from a value of $2.08 billion in 2024 to a worth of $2.2 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. Factors contributing to the growth in the historical period include an increase in respiratory disorders, a rising demand for tailored medicine, an increase in outsourcing by pharmaceutical firms, and the development of the biopharmaceutical industry.

The value of the inhalation CDMO market is forecasted to enjoy robust expansion in the coming years. By 2029, it’s anticipated to scale up to $2.84 billion, with an annual compound growth rate of 6.5%. This anticipated growth within the forecast period can be traced back to factors such as heightened attention to precision medicine and tailored therapies, a fast-paced expansion of biopharmaceutical inhalation therapies, a focus on solutions centered around the patient, worldwide market growth and emerging market potentials, as well as regulatory backing for inhale-able drug development. Key trends projected to shape the sector within the forecast period encompass a growing demand for digital health solutions, biologic inhalation therapies, focus on eco-friendly inhaler technologies, the incorporation of artificial intelligence (AI) and machine learning, collaborations, and partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

What factors are expected to fuel Inhalation CDMO market growth in the coming years?

The rise in respiratory disease occurrences is anticipated to stimulate the expansion of the inhalation CDMO market. Respiratory conditions encompass a variety of health issues impacting the respiratory system, including all organs and structures used in breathing. The knowledge and proficiency of inhalation CDMOs in devising and distributing drugs to the lungs make them instrumental in developing and manufacturing treatments for respiratory disorders. This provides pharmaceutical firms with specialized expertise, infrastructure, and resources needed for creating groundbreaking inhalation therapies. For example, the Australian Bureau of Statistics (ABS), a government agency in Australia, reported that 8.5 million Australians, or 34%, suffer from chronic respiratory diseases, which include 2.8 million, or 11%, with asthma, and 638,000, or 2.5% with COPD. The surging prevalence of such respiratory ailments is thus fuelling the growth of the inhalation CDMO market.

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Dry Powder Inhaler (DPIs): Capsule-Based DPIs, Diskus-Style DPIs, Multi-Dose DPIs, Unit-Dose DPIs

2) By Metered Dose Inhaler (MDIs): Pressurized MDIs (pMDIs), Breath-Actuated MDIs, Soft Mist MDIs

3) By Nebulizer: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Portable Nebulizers

4) By Soft Mist Inhaler: Respimat Inhalers, Other Soft Mist Inhalation Devices

What Future Market Trends Are Projected For The Inhalation CDMO Industry?

Leading firms in the inhalation CDMO market are embracing a strategy of forming collaborative partnerships, which aim to offer specialized drug development and delivery services. These partnerships are typified by their long-term nature, mutual benefits, and the joint pursuit of common objectives. As an example, Hovione, a Contract Development and Manufacturing Organization based in Portugal, formed a strategic alliance with H&T Presspart, a UK-based provider of high-precision metallic and plastic components used in the pharmaceutical sector. This collaboration, established in May 2023, was set up to develop Presspart’s Sunrise Capsule-based Dry Powder Inhaler platform. The fundamental focus of this partnership is the development of innovative technologies capable of delivering higher drug doses and enhancing the efficiency of pulmonary drug delivery.

What Are The Most Active Companies In The Inhalation CDMO Market Today?

Major companies operating in the inhalation CDMO market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Which Regional Markets Are Attracting The Most Investment In Inhalation CDMO?

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2024. The regions covered in the inhalation CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13864&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model